We demonstrate that miR‐186 could regulate METTL3 expression in progression of HB via Wnt/β‐catenin signalling, suggesting the miR‐186/METTL3 axis may be used as an effective therapeutic and prognostic biomarker for HB‐afflicted patients. The gene discussed is METTL3; the disease is hemoglobin measurement.